U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. - Wikidata - wikimedia - TriplyDB

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

http://www.wikidata.org/entity/Q33403209

about

Discovery of Anticancer Agents of Diverse Natural Origin A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model What's fueling the biotech engine-2011 to 2012.Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia.Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.CD30 as a therapeutic target for lymphoma.Industrial natural product chemistry for drug discovery and development.Emerging drugs for T-cell lymphoma.Monoclonal antibodies as therapeutics in human malignancies.Achieving incompatible transplantation through desensitization: current perspectives and future directions.Brentuximab vedotin for the treatment of Hodgkin's lymphoma.Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.The new therapeutical scenario of Hodgkin lymphoma.Ibrutinib in B lymphoid malignancies.Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates.Novel agents for the treatment of Hodgkin lymphoma.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.Antibody-mediated delivery of therapeutics for cancer therapy.Merocyclophanes C and D from the Cultured Freshwater Cyanobacterium Nostoc sp. (UIC 10110).Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma.KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer.Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma.FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.

P2860

Q28068341-85503352-26F3-4FB5-B3AC-D06386DE0BAD Q28487973-061FFF99-8410-4F55-895A-955C71900842 Q28553497-58C97456-59D3-4CE9-B550-9205992C603D Q30240160-A5291208-569A-4C80-9F15-311B66D6591E Q33875604-5A1615A6-5228-4781-9358-3E7C2372D955 Q34316400-2645721F-620D-4393-A214-1E6F1A11F47B Q34325201-290FF4C2-D272-4164-B90F-F256CCEFC948 Q34655256-5185D071-73D4-480E-AE91-009C6FCD27B1 Q34718363-A6B2A5E6-A42B-4B27-95AA-389A23CC8AA8 Q34802443-AE13F264-A54E-4014-B6B2-762A3C8E992D Q35168766-EE6389FA-7A29-49C8-BE05-2BF759E001D8 Q35691210-6BF18842-27B2-44CA-8837-82F07327CF1C Q36207446-BCD04D35-79D0-42D9-A2B9-60CFEF35BE1E Q36264723-EB6C66FC-342E-46B3-8D7C-F70CA563D0FC Q36534677-1782184C-4E50-4DEC-85D2-9B2EBCA2881B Q36797398-0D897293-6B99-4CED-AA77-71550F9557F8 Q36824455-35DC27FC-38E9-4644-B247-D12687D44E6F Q37098844-CB509AD9-A730-4D36-A6F8-E8D9DAD0AA1A Q37412853-93D7A25A-5C64-4E75-A4D5-45C8D9FBA80B Q38131563-6B114EB2-D7F9-4FD8-BF64-6034353F6759 Q38138482-DCB9CEEB-4E9F-43A7-896C-7DE3D811EF85 Q38154186-60CB6281-6563-4B59-8CD9-42CF1B39E41B Q38196943-C10C77DB-2C07-4651-8732-BB66A83D99FF Q38206275-062D1601-9D89-40DD-8CA4-7A40CF579B73 Q38445336-A2AB65CE-AF9E-41C2-AC89-128149ED9F6A Q38476250-970CAC84-B697-499C-A2DB-DD4F9D9CBD31 Q38489049-E4BC6EBB-E6B8-404E-9969-1217628A6005 Q38513816-332C3E30-60AC-40B1-953C-EB3D7EEAB33A Q38545545-5F66CBEC-FC79-4EB3-BF47-E4607484FC2B Q38557519-2D1AD042-2C14-44D7-A99A-760A53DF7112 Q38581830-641C840A-9E53-48A9-9C79-78449AE9AA6D Q38664909-58D0870A-0801-4053-8A5F-962A753F7686 Q38665425-C7955623-C2CC-4B71-9F0F-1B1BC5A54BA8 Q38714213-AFE98CBE-8208-4244-B930-E05B8394EB79 Q38759986-EC13C966-F53D-49E7-A2CE-7AFC8F8C8CD5 Q38781439-8AB42256-CDCC-4224-B326-16C60A111CF4 Q38808823-93B2EA85-D12C-4502-AB44-6548E6CCD7D4 Q38992200-4EFBF466-09F3-42CC-86B8-A1DD6339D349 Q39193590-EA860F92-0FC5-4B99-8592-8CC701A6F9C6 Q39259769-0A58A5F4-CC24-4D24-925C-A169DC5A16C7

P2860

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

http://www.wikidata.org/entity/Q33403209

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

U.S. Food and Drug Administrat ...... naplastic large-cell lymphoma.

@ast

U.S. Food and Drug Administrat ...... naplastic large-cell lymphoma.

@en

type

label

U.S. Food and Drug Administrat ...... naplastic large-cell lymphoma.

@ast

U.S. Food and Drug Administrat ...... naplastic large-cell lymphoma.

@en

prefLabel

U.S. Food and Drug Administrat ...... naplastic large-cell lymphoma.

@ast

U.S. Food and Drug Administrat ...... naplastic large-cell lymphoma.

@en

P1433

Q33403209-767AB143-1765-4832-9D48-4116E7A87695

P1476

Q33403209-BA55BDA8-F00E-4226-ADE1-370477AA848B

P2093

Q33403209-01A02B42-56B3-4DBA-9A0F-2168C47C8289

Q33403209-2463D9B5-14F5-4880-B1C0-942D7A77119F

Q33403209-25323CDC-6003-4D3B-81A1-2D32DCB97045

Q33403209-2580088B-4C5B-4068-ABD8-5A7998BECFFB

Q33403209-28BE1EB9-5AEE-4385-8658-594CDC6CC718

Q33403209-36F7B6DE-E13C-4A60-A927-AC0402B2292A

Q33403209-39F25361-898E-4C8F-B149-D7F2797E4C49

Q33403209-449C7195-01A5-463A-8B5D-C905A8102220

Q33403209-77DEF4A1-5A38-4675-ADA7-8F51E149F08C

Q33403209-837573A4-88CA-4B98-9781-B4DB8BF63134

P304

Q33403209-16C17643-BC88-40F9-830C-15F1F1483975

P31

Q33403209-209960A1-FA96-4145-9274-A9767D567366

P356

Q33403209-B8A82F1D-35F2-4031-A9C0-99EAE15A6520

P407

Q33403209-423D8AC3-91B1-4879-BC28-D6F9A4A28348

P433

Q33403209-D5E39B05-B704-453E-9907-B9869C44BAC3

P478

Q33403209-092416E7-8105-4CF2-B6E7-DBB3F1DB9185

P577

Q33403209-0D8B81C1-1C2E-46E8-989F-8BD075977F8E

P698

Q33403209-EF95E96B-D7C3-4AC0-A796-143533D2F89D

P921

Q33403209-B49F2A44-9429-4211-AC0F-E65B213069A3

P356

1078-0432.CCR-12-1803

P1433

Clinical Cancer Research

P1476

U.S. Food and Drug Administrat ...... naplastic large-cell lymphoma.

@en

P2093

Aakanksha Khandelwal

http://www.w3.org/2001/XMLSchema#string

Ann Farrell

http://www.w3.org/2001/XMLSchema#string

Bahru Habtemariam

http://www.w3.org/2001/XMLSchema#string

Edvardas Kaminskas

http://www.w3.org/2001/XMLSchema#string

Francisco Borrego

http://www.w3.org/2001/XMLSchema#string

Haleh Saber

http://www.w3.org/2001/XMLSchema#string

Janice Brown

http://www.w3.org/2001/XMLSchema#string

Julie Bullock

http://www.w3.org/2001/XMLSchema#string

Kallappa Koti

http://www.w3.org/2001/XMLSchema#string

Karen McGinn

http://www.w3.org/2001/XMLSchema#string

P304

5845-5849

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-1803

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22962441

http://www.w3.org/2001/XMLSchema#string

P921